Form 4 Gyre Therapeutics Inc For: 11 June
- Investing.com
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Gyre Therapeutics Inc (GYRE)
Track today's live Gyre Therapeutics (GYRE) share price, performance and key data on this page with our current NASDAQ:GYRE stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Gyre Therapeutics share price on the NASDAQ exchange. Use the dropdown to switch exchange for the GYRE share price, head to our technical summary section, which provides analysis on Gyre Therapeutics share price buy/sell indicators using real-time data (or discuss the Gyre Therapeutics (GYRE) stock price today with other investors in the Gyre Therapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:GYRE share price (ISIN: US4037831033) to enhance your trading decisions with our free investment tools and resources.
What Is the Gyre Therapeutics Inc Share Price Today?
The Gyre Therapeutics share price today is 5.9300.
What Is the Stock Symbol for Gyre Therapeutics Inc
The stock symbol (or 'ticker') for Gyre Therapeutics Inc is "GYRE."
What Stock Exchange Does Gyre Therapeutics Inc Trade On?
Gyre Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Gyre Therapeutics Inc a Good Stock to Buy?
Determining whether Gyre Therapeutics (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:GYRE share price (ISIN: US4037831033) to enhance your trading decisions with our free investment tools and resources.
What Is the Gyre Therapeutics Inc Share Price Today?
The Gyre Therapeutics share price today is 5.9300.
What Is the Stock Symbol for Gyre Therapeutics Inc
The stock symbol (or 'ticker') for Gyre Therapeutics Inc is "GYRE."
What Stock Exchange Does Gyre Therapeutics Inc Trade On?
Gyre Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Gyre Therapeutics Inc a Good Stock to Buy?
Determining whether Gyre Therapeutics (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.9000
6.0600
52 wk Range
5.4400
9.4200
GYRE is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.90006.0600
52 wk Range
5.44009.4200
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
GYRE Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
18.6667
Upside
+214.78%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
- Form 4 Gyre Therapeutics Inc For: 11 June
- Investing.com
- Form 8K Gyre Therapeutics Inc For: 2 June
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 18.6667
(+214.78% Upside)
Earnings
Latest Release
07/05/2026
EPS / Forecast
-0.10 / -0.07
Revenue / Forecast
22.5M / 37.05M
Compare GYRE to Peers and Sector
Metrics to compare | GYRE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGYREPeersSector | |
|---|---|---|---|---|
P/E Ratio | −85.2x | −8.4x | −0.5x | |
PEG Ratio | 0.18 | −0.08 | 0.00 | |
Price/Book | 5.3x | 4.4x | 2.6x | |
Price / LTM Sales | 4.6x | 12.1x | 3.0x | |
Upside (Analyst Target) | 203.5% | 74.4% | 58.6% | |
Fair Value Upside | Unlock | −4.9% | 10.2% | Unlock |
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Gyre Therapeutics (NASDAQ: GYRE) Share Price Today?
The Gyre Therapeutics stock price today is 5.9300 USD.
What Stock Exchange Does Gyre Therapeutics (GYRE) Trade On?
Gyre Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Gyre Therapeutics?
The stock symbol (also called a 'ticker') for Gyre Therapeutics is "GYRE."
What Is the Current Gyre Therapeutics Market Capitalisation?
As of today, Gyre Therapeutics (NASDAQ: GYRE) market cap is 541.8400M USD.
What Is Gyre Therapeutics's (GYRE) Earnings Per Share (TTM)?
The Gyre Therapeutics EPS is currently -0.0762 (Trailing Twelve Months).
When Is the Next Gyre Therapeutics Earnings Date?
Gyre Therapeutics's next earnings report will be released on 18/08/2026.
Is GYRE a Buy or Sell From a Technical Analyst Perspective?
Based on today's Gyre Therapeutics moving averages and other technical indicators, the daily buy/sell signal for GYRE stock is Strong Sell.
How Many Times Has Gyre Therapeutics Stock Split?
Gyre Therapeutics has split 3 times. (See the GYRE stock split history page for full effective split date and price information.)
How Many Employees Does Gyre Therapeutics Have?
Gyre Therapeutics has 625 employees, based on their latest Companies House report.
What is the current trading status of Gyre Therapeutics (NASDAQ: GYRE)?
As of 13/06/2026, Gyre Therapeutics (GYRE) is trading at a share price of 5.9300 USD, with a previous close of 6.0600 USD. The stock has fluctuated within a day range of 5.9000 USD to 6.0600 USD, while its 52-week range spans from 5.4400 USD to 9.4200 USD.
What Is Gyre Therapeutics (GYRE) Price Target According to Analysts?
The average 12-month price target for Gyre Therapeutics is 18.6667 USD, with a high estimate of 20 USD and a low estimate of 18 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +214.78% Upside potential.
What Is the GYRE Premarket Price?
GYRE's last pre-market stock price is 6.0500 USD. The pre-market share volume is 3,920.0000, and the stock has decreased by -0.0100, or -0.1700%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.